Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.7.49 (
reverse transcriptase
)
31,746
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Down's syndrome (DS), a chromosomal abnormal genetic disease caused by a local or total copy of chromosome 21, leads to patients suffering from delayed body growth, special facies, mild to moderate mental retardation and other symptoms, seriously affecting the life of patients. The aim of the present study was to examine the association between Down's syndrome critical region 4 (
DSCR4
) gene methylation in plasma in high-risk pregnant women with DS in early pregnancy (hereinafter referred to as pregnant women in early pregnancy) and DS, in order to screen new epigenetic markers for the clinical diagnosis of DS. DNA in peripheral blood cells and plasma in pregnant women in early pregnancy were treated with hydrosulphite.
DSCR4
genes with different methylation levels were amplified by methylation-specific polymerase chain reaction (PCR), and the methylation difference of the CpG site of the
DSCR4
amplification product in peripheral blood DNA was verified via restriction endonuclease analysis. The expression of
DSCR4
with different methylation levels in peripheral blood of pregnant women in early pregnancy were detected via
reverse transcriptase
-quantitative PCR (RT-qPCR), and the
DSCR4
gene functions were studied via the intervention in
DSCR4
expression with small interfering RNA (siRNA). Methylation-specific PCR and restriction endonuclease analysis revealed that
DSCR4
genes were differentially methylated in peripheral blood DNA in pregnant women in early pregnancy. Additionally,
DSCR4
showed a low methylation status in plasma but a high methylation status in peripheral blood cells. RT-qPCR revealed that non-methylated
DSCR4
was highly expressed in the peripheral blood of pregnant women in early pregnancy, and thus was an epigenetic marker of fetal DS. siRNA results showed that the downregulation of
DSCR4
inhibited cell migration and invasion, but had no effect on cell proliferation. The results suggest that the
DSCR4
gene was differentially methylated in peripheral blood DNA in pregnant women in early pregnancy. Furthermore,
DSCR4
exists in a non-methylated state in plasma and in a hyper-methylated state in blood cells.
DSCR4
can therefore promote the migration and invasion of trophocytes and serve as an epigenetic marker of non invasive clinical diagnosis of DS.
...
PMID:Association between
DSCR4
gene methylation in plasma in early pregnancy and Down's syndrome. 2945 78